Arbutus Biopharma Corp. Stock
€2.54
Your prediction
Arbutus Biopharma Corp. Stock
Pros and Cons of Arbutus Biopharma Corp. in the next few years
Pros
Cons
Performance of Arbutus Biopharma Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Arbutus Biopharma Corp. | -0.780% | -1.167% | 9.483% | 10.435% | 10.675% | -5.295% | 10.435% |
| Chromadex Corp | 3.160% | -11.732% | -9.714% | 152.800% | 135.821% | -48.618% | - |
| Organovo Holdings Inc. | 1.510% | -15.818% | -3.037% | -43.742% | -9.747% | -88.013% | -94.745% |
| Intellia Therapeutics Inc | 4.360% | -6.811% | -24.819% | -43.546% | -35.492% | -71.154% | 22.419% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Diving into the financials of Arbutus Biopharm, the general impression is that of a company heavily engaged in research and development, which is typical for players in the Biotechnology & Medical Research industry. As the financial statements have revealed, Arbutus Biopharm has robust total assets and has managed to increase its total assets year over year, which is a positive sign of growth. However, the company has also been consistently operating at a loss, with net income figures cementing its position within a challenging and competitive sector where profits often remain elusive until breakthroughs are achieved.
1. Strong Asset Base Arbutus Biopharm's total assets have shown a growth trend over the past years, with the number rising from $137.08M in 2020 to $195.42M in 2022. This indicates an ability to expand and sustain its research endeavors.
2. Robust Investment in R&D A key strength is the company's significant investment in research and development. In 2022, R&D expenses were $84.41M, reflecting the company's commitment to innovation, which is critical for long-term success in biotech.